Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii

K. Y. Look, Frederick Stehman, D. H. Moore, G. P. Sutton

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pseudomyxoma peritoneii has an indolent course but a 5-year survival rate of 40-45%. The role for postoperative intraperitoneal chemotherapy is unclear. Nine patients with pseudomyxoma arising from mucinous neoplasms of the ovary and intestinal tract received a total of 89 courses of intraperitoneal 5-fluorouracil (IPSFU). Each course consisted of eight 4-h exchanges of I g of 5FU in 2 1 of 1.5% Inpersol ®. Median follow-up after diagnosis was 30 months (range 6-74). All patients were evaluable for toxicity and response. There was one treatment-related death due to renal failure and sepsis. Three patients developed disease progression prior to scheduled second-look laparotomy. At second-look laparotomy two patients demonstrated pathologic complete responses, one had stable disease and one had progression of disease. One patient remained clinically free of progression after refusing second-look laparotomy. The projected 5-year survival by Kaplan-Meier estimate was 87% for patients treated with IP5FU compared to a 52% 5-year survival seen in a series of 11 patients treated prior to the use of IPSFU (P = 0.12). This preliminary analysis suggests that IPFU in the described schedule fails to improve survival statistically compared to previously used regimens for patients with pseudomyxoma peritoneii.

Original languageEnglish
Pages (from-to)361-365
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume5
Issue number5
StatePublished - 1995

Fingerprint

Fluorouracil
Laparotomy
Survival
Disease Progression
Intestinal Neoplasms
Kaplan-Meier Estimate
Ovarian Neoplasms
Renal Insufficiency
Sepsis
Appointments and Schedules
Survival Rate
Drug Therapy

Keywords

  • Intraperitoneal 5-fluorouracil
  • Pseudomyxoma peritoneii

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii. / Look, K. Y.; Stehman, Frederick; Moore, D. H.; Sutton, G. P.

In: International Journal of Gynecological Cancer, Vol. 5, No. 5, 1995, p. 361-365.

Research output: Contribution to journalArticle

Look, K. Y. ; Stehman, Frederick ; Moore, D. H. ; Sutton, G. P. / Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii. In: International Journal of Gynecological Cancer. 1995 ; Vol. 5, No. 5. pp. 361-365.
@article{18839fecd3b04af8824c7112ecf14723,
title = "Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii",
abstract = "Pseudomyxoma peritoneii has an indolent course but a 5-year survival rate of 40-45{\%}. The role for postoperative intraperitoneal chemotherapy is unclear. Nine patients with pseudomyxoma arising from mucinous neoplasms of the ovary and intestinal tract received a total of 89 courses of intraperitoneal 5-fluorouracil (IPSFU). Each course consisted of eight 4-h exchanges of I g of 5FU in 2 1 of 1.5{\%} Inpersol {\circledR}. Median follow-up after diagnosis was 30 months (range 6-74). All patients were evaluable for toxicity and response. There was one treatment-related death due to renal failure and sepsis. Three patients developed disease progression prior to scheduled second-look laparotomy. At second-look laparotomy two patients demonstrated pathologic complete responses, one had stable disease and one had progression of disease. One patient remained clinically free of progression after refusing second-look laparotomy. The projected 5-year survival by Kaplan-Meier estimate was 87{\%} for patients treated with IP5FU compared to a 52{\%} 5-year survival seen in a series of 11 patients treated prior to the use of IPSFU (P = 0.12). This preliminary analysis suggests that IPFU in the described schedule fails to improve survival statistically compared to previously used regimens for patients with pseudomyxoma peritoneii.",
keywords = "Intraperitoneal 5-fluorouracil, Pseudomyxoma peritoneii",
author = "Look, {K. Y.} and Frederick Stehman and Moore, {D. H.} and Sutton, {G. P.}",
year = "1995",
language = "English",
volume = "5",
pages = "361--365",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii

AU - Look, K. Y.

AU - Stehman, Frederick

AU - Moore, D. H.

AU - Sutton, G. P.

PY - 1995

Y1 - 1995

N2 - Pseudomyxoma peritoneii has an indolent course but a 5-year survival rate of 40-45%. The role for postoperative intraperitoneal chemotherapy is unclear. Nine patients with pseudomyxoma arising from mucinous neoplasms of the ovary and intestinal tract received a total of 89 courses of intraperitoneal 5-fluorouracil (IPSFU). Each course consisted of eight 4-h exchanges of I g of 5FU in 2 1 of 1.5% Inpersol ®. Median follow-up after diagnosis was 30 months (range 6-74). All patients were evaluable for toxicity and response. There was one treatment-related death due to renal failure and sepsis. Three patients developed disease progression prior to scheduled second-look laparotomy. At second-look laparotomy two patients demonstrated pathologic complete responses, one had stable disease and one had progression of disease. One patient remained clinically free of progression after refusing second-look laparotomy. The projected 5-year survival by Kaplan-Meier estimate was 87% for patients treated with IP5FU compared to a 52% 5-year survival seen in a series of 11 patients treated prior to the use of IPSFU (P = 0.12). This preliminary analysis suggests that IPFU in the described schedule fails to improve survival statistically compared to previously used regimens for patients with pseudomyxoma peritoneii.

AB - Pseudomyxoma peritoneii has an indolent course but a 5-year survival rate of 40-45%. The role for postoperative intraperitoneal chemotherapy is unclear. Nine patients with pseudomyxoma arising from mucinous neoplasms of the ovary and intestinal tract received a total of 89 courses of intraperitoneal 5-fluorouracil (IPSFU). Each course consisted of eight 4-h exchanges of I g of 5FU in 2 1 of 1.5% Inpersol ®. Median follow-up after diagnosis was 30 months (range 6-74). All patients were evaluable for toxicity and response. There was one treatment-related death due to renal failure and sepsis. Three patients developed disease progression prior to scheduled second-look laparotomy. At second-look laparotomy two patients demonstrated pathologic complete responses, one had stable disease and one had progression of disease. One patient remained clinically free of progression after refusing second-look laparotomy. The projected 5-year survival by Kaplan-Meier estimate was 87% for patients treated with IP5FU compared to a 52% 5-year survival seen in a series of 11 patients treated prior to the use of IPSFU (P = 0.12). This preliminary analysis suggests that IPFU in the described schedule fails to improve survival statistically compared to previously used regimens for patients with pseudomyxoma peritoneii.

KW - Intraperitoneal 5-fluorouracil

KW - Pseudomyxoma peritoneii

UR - http://www.scopus.com/inward/record.url?scp=0029157441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029157441&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029157441

VL - 5

SP - 361

EP - 365

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -